Although there were no differences in the overall percentage of all monocytes in the blood of patients and controls (data not shown), more detailed analysis of monocyte subsets revealed fewer classical monocytes (CD14++CD16neg), but significantly more intermediate monocytes (CD14++/+CD16+) in patients with breast cancer. Here, CD14 is linked to breast cancer.